AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02188732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBHH
Description: Community-based Health Home (CBHH): Each team has a staff-to-participant ratio of approximately 1:12, with each team serving approximately 120 participants with SMI using person-centered planning and recovery-oriented, flexible service models. Each team provides mobile outreach and includes a team leader; a peer counselor; a psychiatric nurse coordinator; a clinical care coordinator; specialists in substance abuse (dual diagnosis), community integration, rehabilitation, employment, and housing; and a medical nurse practitioner (MNP) and a health outreach worker (HOW).
Study NCT03011853 — intervention group
Intervention type: PROCEDURE
Intervention: Non-invasive and/or invasive mechanical ventilation
Description: Use of Non-invasive and invasive mechanical ventilation, focussing particularly on the first respiratory support mode in ICU
Study NCT01181882 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil and Aspirin
Description: 4 grams of fish oil each day for 28 days and 81 mg aspirin
Study NCT03991767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: POP-UP electronic alert
Description: Implementation of the POP-UP electronic alert for all patients with eligibility criteria
Study NCT03991767 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serology HIV
Description: Realization of HIV serology for included patients.
Study NCT00134719 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenHibrix (Hib-MenCY-TT)
Description: One intramuscular dose at 2, 4 and 6 months of age ( group A) and one intramuscular dose at 12 to 15 months of age (groups A and B)
Study NCT00134719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenHibrix (Hib-MenCY-TT)
Description: One intramuscular dose at 2, 4 and 6 months of age ( group A) and one intramuscular dose at 12 to 15 months of age (groups A and B)
Study NCT00134719 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix® Penta
Description: One intramuscular dose at 2, 4 and 6 months of age
Study NCT00134719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix® Penta
Description: One intramuscular dose at 2, 4 and 6 months of age
Study NCT00134719 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar®
Description: One intramuscular dose at 2, 4 and 6 months of age
Study NCT00134719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar®
Description: One intramuscular dose at 2, 4 and 6 months of age
Study NCT00134719 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ActHIB®
Description: One intramuscular dose at 2, 4 and 6 months of age
Study NCT00134719 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningitec®
Description: One intramuscular dose at 2, 4 and 6 months of age
Study NCT00134719 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R®II
Description: One subcutaneous dose at 12-15 months of age
Study NCT03628261 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Serious Game
Description: Surface EMG detection for the myoelectric control of the EMG-based serious games and for the EMG assessment during gait will be performed with a wireless system.This device is composed of seven modules (sensor units), each detecting and transmitting two bipolar EMGs at 2 kilo Hertz (kHz). During the evaluation protocol EMGs will be detected from peroneus longus, gastrocnemius medialis, soleus and tibialis anterior muscles of both limbs using pre-gelled electrodes.
Study NCT00134719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R®II
Description: One subcutaneous dose at 12-15 months of age
Study NCT00134719 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varivax®
Description: One subcutaneous dose at 12 to 15 months of age
Study NCT00134719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varivax®
Description: One subcutaneous dose at 12 to 15 months of age
Study NCT00134719 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PedvaxHIB®
Description: One intramuscular dose at 12 to 15 months of age
Study NCT02961660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir
Description: Participants will receive odalasvir 25 mg tablet, orally.
Study NCT03154606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Micellar Casein (#1)
Description: The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from micellar casein. All ingredients are GRAS listed and approved.
Study NCT03154606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Micellar Casein (#2)
Description: The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from micellar casein. All ingredients are GRAS listed and approved.
Study NCT03154606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calcium Caseinate
Description: The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from calcium casein. All ingredients are GRAS listed and approved.
Study NCT03154606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Caseinate
Description: The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from sodium caseinate. All ingredients are GRAS listed and approved.
Study NCT03154606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk Protein Isolate
Description: The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from milk protein caseinate. All ingredients are GRAS listed and approved.
Study NCT03154606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pure Protein Blend
Description: The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from pure protein blend. All ingredients are GRAS listed and approved.
Study NCT03154606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate
Description: The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from whey protein blend. All ingredients are GRAS listed and approved.
Study NCT03154606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Native Whey Protein Isolate
Description: The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from Native Whey Protein Isolate. All ingredients are GRAS listed and approved.
Study NCT03154606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soy Protein
Description: The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from soy protein. All ingredients are GRAS listed and approved.
Study NCT03154606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea Protein
Description: The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from pea protein. All ingredients are GRAS listed and approved.
Study NCT03154606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Native Whey: Micellar Casein (50:50) blend
Description: The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from native whey: micellar casein (50:50) blend. All ingredients are GRAS listed and approved.
Study NCT03154606 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate Control
Description: The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to \~250 kcal. The meals will include the same fat content but will contain predominantly carbohydrates as a control. All ingredients are GRAS listed and approved.
Study NCT03987048 — intervention group
Intervention type: OTHER
Intervention: Measure of short- and long-term mortality and analysis of independent predictors of short- and long-term mortality.
Description: Data were collected regarding medical background, medical condition and management, both at admission and during the ICU stay. These included demographics, clinical, biological and therapeutic data.~Outcome at ICU discharge and at one year were also recorded.
Study NCT02939391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356
Description: Oral administration
Study NCT02939391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study NCT01794780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAMA based treatment: tiotropium
Description: LAMA based treatment: tiotropium
Study NCT01794780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABA/ICS based treatment: salmeterol/fluticasone
Description: LABA/ICS based treatment: salmeterol/fluticasone
Study NCT01794780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABA/ICS based treatment: budesonide/formoterol
Description: LABA/ICS based treatment: budesonide/formoterol
Study NCT01794780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: theophylline based treatment
Description: theophylline based treatment
Study NCT01794780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other treatment
Description: non-long-acting bronchodilators for COPD treatment, such treatments were classified as other treatments
Study NCT01400737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively.
Study NCT01400737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively
Study NCT04407377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolperisone Hydrochloride
Description: Study Drug
Study NCT04407377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine Hydrochloride 10 MG
Description: Active Comparator
Study NCT04407377 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT02934607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort pMDI with spacer device
Description: Relative bioavailability of budesonide and formoterol delivered via Symbicort pressurized metered-dose inhaler (pMDI) with a spacer device (test)
Study NCT02934607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort pMDI without spacer device
Description: Relative bioavailability of budesonide and formoterol delivered via Symbicort pMDI without a spacer device (reference)
Study NCT01819792 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multiplex respiratory viral PCR
Study NCT03839602 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reducing CTV
Description: CTVs were delineated in line with tumor stage, i.e. tumor invasion.
Study NCT02491541 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Changchun Werersai
Description: A rabies vaccine (Vero Cell) for human use produced by Changchun Werersai Biotech Pharmaceutical Co., Ltd.~1.0 ml experimental vaccine on day 0,3,7,14,28
Study NCT02491541 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Jilin Maifeng
Description: A rabies vaccine (Vero Cell) for human use produced by Jilin Maifeng Biotech Pharmaceutical Co., Ltd.~1.0 ml comparator vaccine on day 0,3,7,14,28
Study NCT03628261 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: physical therapy
Description: Children receive the regular rehabilitation for the treatment of ankle plantar flexor muscle overactivity and the paresis of ankle dorsal flexor muscle
Study NCT02666599 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Description: A 18F-FDG PET/CT will be done. A dose of 19 µSv/MBq will be received by the patient. Surgery will be conducted within 3 hours after the I.V. injection of 18F-FDG according to the standard procedure applied in the visceral surgery department. During the surgery, emission of β+ from the lesion (s) seen durint the PET/CT will be detected with the probe.~Resected pieces will be analysed histologically.
Study NCT04663672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Scent
Description: Participants will sleep in the presence of the exposure scent, delivered by an Airwick Essential Oils diffuser
Study NCT04663672 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Scent
Description: Participants will sleep in the presence of a novel scent, delivered by an Airwick Essential Oils diffuser
Study NCT01924702 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive language therapy
Description: 2 weeks of daily computerized naming training, daily, 3 hours
Study NCT01924702 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Intensive language therapy
Description: 2 weeks of daily computerized naming training, daily, 3 hours
Study NCT01924702 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: 1mA anodal over M1 primary motor cortex for 20min with 35cm/2 electrode, Cathode (100cm/2) contralateral
Study NCT01924702 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: 1mA anodal over M1 primary motor cortex for 20min with 35cm/2 electrode, Cathode (100cm/2) contralateral
Study NCT03272269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMCY-0098
Description: Small synthetic peptide for SC admin. Solvent: alum hydroxide
Study NCT03272269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solvent: alum hydroxide
Study NCT03426982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Description: Infusion dose of unfractionated heparin was adjusted by APTT
Study NCT03426982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Description: Infusion dose of unfractionated heparin was adjusted by anti-Xa
Study NCT04001140 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhancement of emotion regulation skills
Description: Regarding the intervention, 7 sessions will be carried out. The main purpose is to help adolescents to enhance their emotion regulation, with the ultimate goal to decrease their risk of developing addictions and other psychopathology.
Study NCT03690336 — intervention group
Intervention type: DRUG
Intervention: Nonacog beta pegol
Description: Treatment with commercially available nonacog beta pegol according to routine clinical practice at the discretion of the treating physician.
Study NCT02814331 — intervention group
Intervention type: DEVICE
Intervention: multimodal high-resolution EEG-NIRS
Study NCT04173208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal microbial transplant
Description: Fecal microbial transplant
Study NCT04173208 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00704522 — intervention group
Intervention type: BIOLOGICAL
Intervention: Peginterferon alfa-2b (SCH 54031)
Description: Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
Study NCT00704522 — intervention group
Intervention type: DRUG
Intervention: Ribavirin (SCH 18908)
Description: Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
Study NCT00704522 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient assistance program
Description: Assistance programs will be classified as follows:~1. Medications used prophylactically or for treatment(Growth factors: RBC and neutrophil; Psychiatric medications; Other medications)~2. Other interventions (Psychotherapy, Patient Support Groups, Visiting Nurse, Nurse Telephone Calls, Nurse support in office, Other health care professional support, Educational Literature).~In Austria, sites with adherence nurses and side effect handouts will be compared with sites using side effect handouts only.
Study NCT06335901 — intervention group
Intervention type: DRUG
Intervention: Drug:Standard therapy
Description: Percutaneous coronary Intervention
Study NCT03486145 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fruit and vegetable juice supplement
Description: FVS was provided by Isagenix International LLC in identically sealed bottles labeled labeled B. Subjects were not told which supplement they received. Each bottle contained one serving (two ounces) of the supplement.
Study NCT03486145 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PRU was provided by Isagenix International LLC in identically sealed bottles labeled labeled A. Subjects were not told which supplement they received. Each bottle contained one serving (two ounces) of the supplement.
Study NCT04191083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor imagery
Description: This group will perform motor imagery training on motor learning of different motor tasks
Study NCT04191083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Double time motor imagery
Description: This group will perform motor imagery training by doubling the intervention time to the motor imagery group on motor learning of various motor tasks.
Study NCT04191083 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action observation
Description: This group will perform action observation training on motor learning of various motor tasks.
Study NCT04191083 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: This group will watch a video of a landscape without the presence of people.
Study NCT01413633 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cholecystectomy
Description: single incision laparoscopic cholecystectomy
Study NCT02475824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam®
Description: midazolam (0.05 mg/kg, 30% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea)
Study NCT02475824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam®
Description: midazolam (0.05 mg/kg, 30% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea)
Study NCT02475824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine (pethidine®)
Description: Meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea).
Study NCT02475824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meperidine (pethidine®)
Description: Meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea).
Study NCT02475824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol®
Description: Repeated doses of 10-20 mg propofol are titrated to achieve the target level of sedation.
Study NCT02475824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Precedex®)
Description: Dexmedetomidine (1μg/kg/h, Precedex; Hospira, Seoul, Republic of Korea) or the same volume of normal saline were administered in the MMD and midazolam-meperidine group
Study NCT01302977 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetal tracheal occlusion
Description: Insertion of a detachable balloon inside fetal trachea by percutaneous fetoscopy
Study NCT04399746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: 6mg once daily in day 0,1,7 and 8
Study NCT04399746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 500mg once daily for 4 days
Study NCT04399746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 400 IU twice daily for 30 days